Takeda Pharmaceutical Co. Ltd. President of Research and Development Andrew Plump's teams will be focused on the integration of Shire PLC's drug candidates into the Japanese pharma's R&D organization over the coming months, and the company's ongoing investments in artificial intelligence, machine learning and digital health may help ensure that the combined pipeline's programs are developed efficiently.
Plump insisted in an interview during the J.P. Morgan Healthcare Conference, conducted a day after Takeda closed its $61bn Shire purchase, that much of the work to rationalize Shire's R&D pipeline in the context of Takeda's strategic priorities has taken place during the past few years as the acquirer has trimmed its R&D organization